Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Terrance May

Clinical Cardiac Electrophysiology Roanoke, VA Medical Doctor

NPI 1316948128 CMS profile 241524

2001 Crystal Spring Ave Sw Ste 203, Roanoke, VA 24014

Open in the dashboard

General payments

$10,125

157 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Terrance May of Roanoke, VA is reported in the CMS Open Payments database as having received $10,125 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 34th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $91 2
2024 General $456 17
2023 General $4,430 54
2022 General $1,176 11
2021 General $607 23
2020 General $1,552 31
2019 General $1,813 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Terrance May
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Terrance May were reported at $91. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Terrance May Clinical Cardiac Electrophysiology median Middle half National median
2019 $1,813 $2,361 $585–$8,260 $163
2020 $1,552 $993 $247–$4,351 $114
2021 $607 $1,185 $326–$4,739 $132
2022 $1,176 $2,073 $554–$6,789 $149
2023 $4,430 $2,568 $759–$8,159 $160
2024 $456 $2,557 $703–$7,403 $164
2025 $91 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $5,757 74 payments
  2. Abbott Laboratories $1,721 14 payments
  3. Boston Scientific Corporation $1,185 43 payments
  4. Medtronic Vascular, Inc. $1,111 22 payments
  5. iRhythm Technologies, Inc. $238 2 payments
  6. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $112 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,764 140 payments
  2. Travel and Lodging $3,291 16 payments
  3. Education $70 1 payment
Products named General payments · program years 2019–2025
  1. ViewMate Intracardiac Echo $1,136 9 payments
  2. COBALT DR MRI SURESCAN $944 16 payments
  3. SelectSecure $484 6 payments
  4. MICRA Pacemakers $445 9 payments
  5. Claria MRI $348 6 payments
  6. Cobalt $246 6 payments
  7. Micra Pacemakers $225 7 payments
  8. LUX-Dx Insertable Cardiac Monitor $196 9 payments
  9. Quadra Allure MP RF CRT Pacemkr $165 1 payment
  10. VIGILANT $156 4 payments
  11. Other $2,083 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

3,627

Median for Cardiology: 2,533

Drug cost

$1,133,838

Median for Cardiology: $485,213

Branded share of claims

37.6%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 698 $743,086
Entresto Sacubitril/Valsartan Brand 242 $257,866
Xarelto Rivaroxaban Brand 29 $43,524
Jardiance Empagliflozin Brand 30 $32,117
Farxiga Dapagliflozin Propanediol Brand 13 $20,933
Flecainide Acetate Generic 184 $5,723
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 182 $4,705
Metoprolol Succinate Generic 322 $3,698
Dofetilide Generic 28 $2,434
Nebivolol Hcl Generic 38 $2,369

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 66 billing codes

Paid by Medicare

$179,991

Medicare's payments for the services billed

Medicare patients

1,349

Average age 78

Services billed

2,504

619 women, 730 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 62%
Heart failure 50%
Ischemic heart disease 47%
Arthritis 46%
Chronic kidney disease 40%
Diabetes 37%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record